awmsg logo



tacrolimus (Advagraf®)


Reference No. 820

Publication date:
07/09/2011


Appraisal information

tacrolimus (Advagraf®) 0.5 mg prolonged-release capsule
tacrolimus (Advagraf®) 1 mg prolonged-release capsule
tacrolimus (Advagraf®) 3 mg prolonged-release capsule
tacrolimus (Advagraf®) 5 mg prolonged-release capsule


Company: Astellas Pharma Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: 11/05/2011
AWMSG meeting date: 15/06/2011
   
   
Submission Type: Resubmission
Status: Superseded
Advice No: 0811
Ministerial ratification: 01/09/2011

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA481) NICE GUIDANCE ISSUED OCTOBER 2017 (Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology)
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download